Cite
HARVARD Citation
Kimball, A. et al. (2020). Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. British journal of dermatology. pp. 1359-1368. [Online].